Shares of Avidity Biosciences, Inc. (RNA) plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.
According to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 million.
The disappointing financial performance weighed heavily on investor sentiment, as Avidity Biosciences' shares faced selling pressure throughout the trading day. Analysts expressed concerns over the company's ability to meet its growth targets, citing the revenue shortfall as a potential red flag.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。